Related Experiment Video
Updated: Jul 14, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
[Type 1 glutaric aciduria: clinical and therapeutic implications].
P E Jiménez Caballero1, C Marsal Alonso
1Sección de Neurología, Hospital Virgen de la Salud, Toledo. pjimenez1010j@yahoo.es
Neurologia (Barcelona, Spain)
|May 18, 2007
Summary
Early treatment for Type 1 glutaric aciduria, a genetic disorder causing dystonia, can reduce symptom severity. Continued therapy may help even after childhood, suggesting long-term benefits for glutaric aciduria patients.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Type 1 glutaric aciduria results from glutaryl CoA dehydrogenase deficiency.
- This leads to elevated glutaric acid and 3-OH glutaric acid, causing dystonia.
- Symptoms manifest after an initial asymptomatic period, presenting acutely or insidiously.
Observation:
- A 16-year-old female presented with macrocrania and insidious left-sided dystonia from 6 months of age.
- She received early treatment due to a sibling diagnosed with Type 1 glutaric aciduria.
- Her clinical presentation was less severe than her sister's, despite sharing the same genotype.
Findings:
- Early intervention with Carnitine, protein restriction, and metabolic management can decrease encephalopathic episodes.
- Even with insidious symptom onset, early treatment may lead to reduced disease severity.
- Genetic factors and consanguinity are important considerations for diagnosis.
Implications:
- Type 1 glutaric aciduria should be suspected in cases of dystonic cerebral palsy, especially with paternal consanguinity.
- Sustained therapeutic approaches may be beneficial beyond the typical age range for acute encephalopathy.
- This case highlights the potential for improved outcomes with proactive and prolonged management of this rare metabolic disorder.
Related Concept Videos
01:27Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
01:30Acute Pancreatitis II: Clinical Manifestations and Management
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...